The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995–2012

European Journal of Health Economics

Volumn 17, Issue 7, 2016, Pages 833-854

  Lichtenberg, Frank R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer; Chemotherapy; Innovation; Longevity; Mortality; Neoplasm; Pharmaceutical

Indexed keywords

ANTINEOPLASTIC AGENT; PRESCRIPTION DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; COST; DRUG INDICATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PREMATURE MORTALITY; PRIORITY JOURNAL; SWITZERLAND; COST BENEFIT ANALYSIS; ECONOMICS; MASS COMMUNICATION; MORTALITY; NEOPLASMS; ONSET AGE; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

AGE OF ONSET; COST-BENEFIT ANALYSIS; DIFFUSION OF INNOVATION; HUMANS; MODELS, ECONOMETRIC; MORTALITY, PREMATURE; NEOPLASMS; PRESCRIPTION DRUGS; QUALITY-ADJUSTED LIFE YEARS; SWITZERLAND;

EID: 84940833595     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-015-0725-6     Document Type: Article

References (21)

1. Association of Public Health Epidemiologists in Ontario. Calculating potential years of life lost (PYLL) (2015). http://www.apheo.ca/index.php?pid=190
2. Burnet, N.G., Jefferies, S.J., Benson, R.J., Huntm D.P., Treasure, F.P.: Years of life lost (YLL) from cancer is an important measure of population burden–and should be considered when allocating research funds. Br J Cancer 92(2), 241–5 (2005). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361853/
3. Commonwealth Fund.: The US Health System in perspective: a comparison of twelve industrialized nations (2011)
4. Dorsey, E.R., et al.: Financial anatomy of biomedical research, 2003–2008. J Am Med Assoc 303(2), 137–143 (2010)
5. Feinstein, A.R., Sosin, D.M., Wells, C.K.: The Will Rogers phenomenon. stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312, 1604–1608 (1985)
6. Hirth, R.A., Chernew, M.E., Miller, E., Fendrick, A.M., Weissert, W.G.: Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 20(3), 332–342 (2000). http://users.phhp.ufl.edu/jharman/healthecon/Hirth%20WTP%20QALY.pdf
7. Jalan, J., Ravallion, M.: Does piped water reduce diarrhea for children in rural India?, World Bank Development Research Group, Policy Research Working Paper 2664 (2001). http://www1.worldbank.org/prem/poverty/ie/dime_papers/332.pdf
8. Lichtenberg, F.R.: The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Econ Innov New Technol 18(5), 407–428 (2009)
9. Lichtenberg, F.R.: The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009. Econ Hum Biol 13, 107–127 (2014)
10. Lichtenberg, F.R.: Has medical innovation reduced cancer mortality? CESifo Econ Stud 60(1), 135–177 (2014)
11. Lichtenberg, F.R.: The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997–2010. J Hum Capital 8(4), 432–480 (2014)
12. McKinnish, T.: Panel data models and transitory fluctuations in the explanatory variable. In: Fomby, T., Hill, R.C., Millimet, D.L., Smith, J.A., Vytlacil, E.J. (eds.) Modelling and evaluating treatment effects in econometrics. Advances in econometrics, vol. 21, pp. 335–358. Emerald Group Publishing Limited, Bradford (2008)
13. National Cancer Institute: Cancer screening overview (2015a). http://www.cancer.gov/cancertopics/pdq/screening/overview/patient/page5
14. National Cancer Institute: Drug discovery at the National Cancer Institute (2015b). http://www.cancer.gov/cancertopics/factsheet/NCI/drugdiscovery
15. Nobelprize.org: The prize in economics 1987—press release (2015). http://www.nobelprize.org/nobel_prizes/economic-sciences/laureates/1987/press.html
16. Renard, F., Tafforeau, J., Deboosere, P.: Premature mortality in Belgium in 1993–2009: leading causes, regional disparities and 15 years change. Arch Public Health 72(1), 34 (2014)
17. Romer, P.: Endogenous technological change. J Polit Econ 98(5, Part 2), S71–S102 (1990)
18. Sampat, B.N., Lichtenberg, F.R.: What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Aff 30(2), 332–339 (2011)
19. Solow, R.M.: Investment and technological progress. In: Arrow, K., Karlin, S., Suppes, P. (eds.) Mathematical methods in social sciences 1959, pp. 89–104. Stanford University Press, Stanford (1960)
20. Stukel, T.A., Fisher, E.S., Wennberg, D.E., Alter, D.A., Gottlieb, D.J., Vermeulen, M.J.: Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297(3), 278–285 (2007). http://jama.jamanetwork.com/article.aspx?articleid=205172
21. World Health Organization: ICD-10 Version 2015, Chapter II, Neoplasms (2015). http://apps.who.int/classifications/icd10/browse/2015/en#/II